Targets for cancer therapy in childhood sarcomas

Cancer Treatment Reviews

Volumn 36, Issue 4, 2010, Pages 318-327

  Wachtel, Marco ^a   Schäfer, Beat W ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Ewing's sarcoma; Molecular targets; Osteosarcoma; Rhabdomyosarcoma; Targeted cancer therapy

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; AMG 479; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BI 2356; BORTEZOMIB; CANCER VACCINE; CEDIRANIB; CP 751871; DASATINIB; DEFOROLIMUS; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMC A 12; INTERLEUKIN 2; IPILIMUMAB; LEXATUMUMAB; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PROTEIN TYROSINE KINASE; R 1507; RAPAMYCIN; ROSCOVITINE; SCH 717454; SUNITINIB; TANESPIMYCIN; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; CANCER SURVIVAL; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DEACETYLATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; EWING SARCOMA; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LYMPHOCYTE; OSTEOSARCOMA; PROTEIN PHOSPHORYLATION; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CHILD; CYCLIN-DEPENDENT KINASES; HISTONE DEACETYLASE INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SARCOMA;

EID: 77953019735     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.02.007     Document Type: Review

References (198)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA: Cancer J Clin 2007, 57:43-66.
2. Linabery A.M., Ross J.A. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer 2008, 113:2575-2596.
3. Landier W, Bhatia S. Cancer survivorship: a pediatric perspective. Oncologist 2008.
4. Benson J.D., Chen Y.N., Cornell-Kennon S.A., et al. Validating cancer drug targets. Nature 2006, 441:451-456.
5. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res 2008, 68:3077-3080.
6. Baselga J., Arribas J. Treating cancer's kinase 'addiction'. Nat Med 2004, 10:786-787.
7. van der Geer P., Hunter T., Lindberg R.A. Receptor protein - tyrosine kinases and their signal transduction pathways. Ann Rev Cell Biol 1994, 10:251-337.
8. Helman L.J., Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003, 3:685-694.
9. Sachdev D., Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007, 6:1-12.
10. Scotlandi K., Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008, 20:419-427.
11. Martins A.S., Mackintosh C., Martin D.H., et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006, 12:3532-3540.
12. Scotlandi K., Avnet S., Benini S., et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 2002, 101:11-16.
13. Scotlandi K., Benini S., Nanni P., et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 1998, 58:4127-4131.
14. Kalebic T., Tsokos M., Helman L.J. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 1994, 54:5531-5534.
15. Kalebic T., Blakesley V., Slade C., Plasschaert S., Leroith D., Helman L.J. Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer 1998, 76:223-227.
16. Manara M.C., Landuzzi L., Nanni P., et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007, 13:1322-1330.
17. Scotlandi K., Maini C., Manara M.C., et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 2002, 9:296-307.
18. Maloney E.K., McLaughlin J.L., Dagdigian N.E., et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003, 63:5073-5083.
19. Kolb E.A., Gorlick R., Houghton P.J., et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1190-1197.
20. Scotlandi K., Manara M.C., Nicoletti G., et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005, 65:3868-3876.
21. Cao L., Yu Y., Darko I., et al. Addiction to elevated insulin-like growth factor i receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008, 68:8039-8048.
22. Naka T., Iwamoto Y., Shinohara N., Ushijima M., Chuman H., Tsuneyoshi M. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol 1997, 10:832-838.
23. Patane S., Avnet S., Coltella N., et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 2006, 66:4750-4757.
24. Scotlandi K., Baldini N., Oliviero M., et al. Expression of met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 1996, 149:1209-1219.
25. Coltella N., Manara M.C., Cerisano V., et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J 2003, 17:1162-1164.
26. MacEwen E.G., Kutzke J., Carew J., et al. C-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis 2003, 20:421-430.
27. Ferracini R., Olivero M., Di Renzo M.F., et al. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 1996, 12:1697-1705.
28. Jankowski K., Kucia M., Wysoczynski M., et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003, 63:7926-7935.
29. Rees H., Williamson D., Papanastasiou A., et al. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors (Chur, Switzerland) 2006, 24:197-208.
30. Sharp R., Recio J.A., Jhappan C., et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002, 8:1276-1280.
31. Taulli R., Scuoppo C., Bersani F., et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006, 66:4742-4749.
32. Migliore C., Giordano S. Molecular cancer therapy: can our expectation be MET?. Eur J Cancer 2008, 44:641-651.
33. Armistead P.M., Salganick J., Roh J.S., et al. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 2007, 110:2293-2303.
34. Kubo T., Piperdi S., Rosenblum J., et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008, 112:2119-2129.
35. Sulzbacher I., Traxler M., Mosberger I., Lang S., Chott A. Platelet-derived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 2000, 13:632-637.
36. Scotlandi K., Manara M.C., Strammiello R., et al. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 2003, 21:1952-1960.
37. Bozzi F., Tamborini E., Negri T., et al. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors. Cancer 2007, 109:1638-1645.
38. Smithey B.E., Pappo A.S., Hill D.A. C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 2002, 26:486-492.
39. Do I., Araujo E.S., Kalil R.K., et al. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. Pathol Res Pract 2007, 203:127-134.
40. McDowell H.P., Meco D., Riccardi A., et al. Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. Int J Cancer 2007, 120:1141-1149.
41. McGary E.C., Weber K., Mills L., et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002, 8:3584-3591.
42. Sulzbacher I., Birner P., Trieb K., Traxler M., Lang S., Chott A. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 2003, 16:66-71.
43. Gonzalez I., Andreu E.J., Panizo A., et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004, 10:751-761.
44. Merchant M.S., Woo C.W., Mackall C.L., Thiele C.J. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002, 94:1673-1679.
45. Taniguchi E., Nishijo K., McCleish A.T., et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008, 27:6550-6560.
46. Beppu K., Jaboine J., Merchant M.S., Mackall C.L., Thiele C.J. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004, 96:46-55.
47. Maris J.M., Courtright J., Houghton P.J., et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 51:42-48.
48. Bond M., Bernstein M.L., Pappo A., et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2008, 50:254-258.
49. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
50. Crabbe T., Welham M.J., Ward S.G. The PI3K inhibitor arsenal: choose your weapon!. Trends Biochem Sci 2007, 32:450-456.
51. Trotman L.C., Pandolfi P.P. PTEN and p53: who will get the upper hand?. Cancer Cell 2003, 3:97-99.
52. Workman P., Clarke P.A., Guillard S., Raynaud F.I. Drugging the PI3 kinome. Nat Biotechnol 2006, 24:794-796.
53. Yap T.A., Garrett M.D., Walton M.I., Raynaud F., de Bono J.S., Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008, 8:393-412.
54. Mateo-Lozano S., Tirado O.M., Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 2003, 22:9282-9287.
55. Gordon I.K., Ye F., Kent M.S. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs. Am J Vet Res 2008, 69:1079-1084.
56. Petricoin E.F., Espina V., Araujo R.P., et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007, 67:3431-3440.
57. Hosoi H., Dilling M.B., Shikata T., et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999, 59:886-894.
58. Houghton P.J., Morton C.L., Kolb E.A., et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:799-805.
59. Wan X., Shen N., Mendoza A., Khanna C., Helman L.J. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006, 8:394-401.
60. Huang S., Shu L., Dilling M.B., et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell 2003, 11:1491-1501.
61. Kurmasheva R.T., Harwood F.C., Houghton P.J. Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther 2007, 6:1620-1628.
62. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
63. Fouladi M., Laningham F., Wu J., et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007, 25:4806-4812.
64. Wan X., Harkavy B., Shen N., Grohar P., Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
65. Thimmaiah K.N., Easton J., Huang S., et al. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. Cancer Res 2003, 63:364-374.
66. Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001, 1:222-231.
67. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006, 24:1770-1783.
68. Baer C., Nees M., Breit S., et al. Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma. Int J Cancer 2004, 110:687-694.
69. Zhang J., Hu S., Schofield D.E., Sorensen P.H., Triche T.J. Selective usage of D-type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res 2004, 64:6026-6034.
70. Ohali A., Avigad S., Zaizov R., et al. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 2004, 23:8997-9006.
71. Kovar H., Jug G., Aryee D.N., et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997, 15:2225-2232.
72. Dauphinot L., De Oliveira C., Melot T., et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene 2001, 20:3258-3265.
73. Iolascon A., Faienza M.F., Coppola B., et al. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer 1996, 15:217-222.
74. Maelandsmo G.M., Berner J.M., Florenes V.A., et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas - relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 1995, 72:393-398.
75. Obana K., Yang H.W., Piao H.Y., et al. Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors. Int J Oncol 2003, 23:1151-1157.
76. Roeb W., Boyer A., Cavenee W.K., Arden K.C. PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proc Natl Acad Sci USA 2007, 104:18085-18090.
77. Miller C.W., Aslo A., Campbell M.J., Kawamata N., Lampkin B.C., Koeffler H.P. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 1996, 86:136-142.
78. Li Y., Tanaka K., Li X., et al. Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells. Int J Cancer 2007, 121:1212-1218.
79. Li X., Tanaka K., Nakatani F., et al. Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells. Int J Cancer 2005, 116:385-394.
80. Tirado O.M., Mateo-Lozano S., Notario V. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res 2005, 65:9320-9327.
81. Bettayeb K., Tirado O.M., Marionneau-Lambot S., et al. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res 2007, 67:8325-8334.
82. Saab R., Bills J.L., Miceli A.P., et al. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther 2006, 5:1299-1308.
83. Boerner S.A., Tourne M.E., Kaufmann S.H., Bible K.C. Effect of P-glycoprotein on flavopiridol sensitivity. Br J Cancer 2001, 84:1391-1396.
84. Whitlock J.A., Krailo M., Reid J.M., et al. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2005, 23:9179-9186.
85. Morris D.G., Bramwell V.H., Turcotte R., et al. A phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma 2006, 64374.
86. Ganjavi H., Gee M., Narendran A., Freedman M.H., Malkin D. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 2005, 12:397-406.
87. Ganjavi H., Gee M., Narendran A., et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 2006, 13:415-419.
88. Shetty S., Taylor A.C., Harris L.C. Selective chemosensitization of rhabdomyosarcoma cell lines following wild-type p53 adenoviral transduction. Anticancer Drugs 2002, 13:881-889.
89. Lock R., Carol H., Houghton P.J., et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1181-1189.
90. Ashkenazi A., Pai R.C., Fong S., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162.
91. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008, 27:6207-6215.
92. Walczak H., Degli-Esposti M.A., Johnson R.S., et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997, 16:5386-5397.
93. Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 2000, 6:4119-4127.
94. Kontny H.U., Hammerle K., Klein R., Shayan P., Mackall C.L., Niemeyer C.M. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Cell Death Differ 2001, 8:506-514.
95. Van Valen F., Fulda S., Truckenbrod B., et al. Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Cancer 2000, 88:252-259.
96. Kumar A., Jasmin A., Eby M.T., Chaudhary P.M. Cytotoxicity of Tumor necrosis factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines. Oncogene 2001, 20:1010-1014.
97. Mitsiades N., Poulaki V., Mitsiades C., Tsokos M. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 2001, 61:2704-2712.
98. Hotta T., Suzuki H., Nagai S., et al. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J Orthop Res 2003, 21:949-957.
99. Mirandola P., Sponzilli I., Gobbi G., et al. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins. Int J Oncol 2006, 28:127-133.
100. Evdokiou A., Bouralexis S., Atkins G.J., et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002, 99:491-504.
101. Lissat A., Vraetz T., Tsokos M., et al. Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol 2007, 170:1917-1930.
102. Komdeur R., Meijer C., Van Zweeden M., et al. Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Int J Oncol 2004, 25:677-684.
103. Tomek S., Koestler W., Horak P., et al. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer 2003, 39:1318-1329.
104. Clayer M., Bouralexis S., Evdokiou A., Hay S., Atkins G.J., Findlay D.M. Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: a potential new approach using TRAIL. J Orthop Surg (Hong Kong) 2001, 9:19-22.
105. Izeradjene K., Douglas L., Delaney A., Houghton J.A. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res 2004, 10:6650-6660.
106. Locklin R.M., Federici E., Espina B., Hulley P.A., Russell R.G., Edwards C.M. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther 2007, 6:3219-3228.
107. Montagut C., Rovira A., Albanell J. The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 2006, 8:313-317.
108. Bersani F., Taulli R., Accornero P., et al. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur J Cancer 2008, 44:876-884.
109. Lu G., Punj V., Chaudhary P.M. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 2008, 7:603-608.
110. Lauricella M., D'Anneo A., Giuliano M., et al. Induction of apoptosis in human osteosarcoma Saos-2 cells by the proteasome inhibitor MG132 and the protective effect of pRb. Cell Death Differ 2003, 10:930-932.
111. Yan X.B., Yang D.S., Gao X., Feng J., Shi Z.L., Ye Z. Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132. Cell Biol Int 2007, 31:1136-1143.
112. Houghton P.J., Morton C.L., Kolb E.A., et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:37-45.
113. Maki R.G., Kraft A.S., Scheu K., et al. A multicenter phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 2005, 103:1431-1438.
114. Cullinan S.B., Whitesell L. Heat shock protein 90: a unique chemotherapeutic target. Semin Oncol 2006, 33:457-465.
115. Lesko E., Gozdzik J., Kijowski J., Jenner B., Wiecha O., Majka M. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo. Anticancer Drugs 2007, 18:1173-1181.
116. Smith M.A., Morton C.L., Phelps D.A., et al. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 51:34-41.
117. Martins A.S., Ordonez J.L., Garcia-Sanchez A., et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res 2008, 68:6260-6270.
118. Bagatell R., Beliakoff J., David C.L., Marron M.T., Whitesell L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer 2005, 113:179-188.
119. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev 2006, 5:769-784.
120. Kelly W.K., Marks P.A. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract 2005, 2:150-157.
121. Karagiannis T.C., El-Osta A. Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer. Epigenetics 2006, 1:121-126.
122. Sakimura R., Tanaka K., Nakatani F., et al. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 2005, 116:784-792.
123. Nakatani F., Tanaka K., Sakimura R., et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 2003, 278:15105-15115.
124. Sonnemann J., Dreyer L., Hartwig M., et al. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol 2007, 133:847-858.
125. Jaboin J., Wild J., Hamidi H., et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002, 62:6108-6115.
126. Imai T., Adachi S., Nishijo K., et al. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 2003, 22:9231-9242.
127. Roh M.S., Kim C.W., Park B.S., et al. Mechanism of histone deacetylase inhibitor trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis 2004, 9:583-589.
128. Kutko M.C., Glick R.D., Butler L.M., et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 2003, 9:5749-5755.
129. Yamanegi K, Yamane J, Hata M, et al. Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death. J Cancer Res Clin Oncol 2008.
130. Watanabe K., Okamoto K., Yonehara S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 2005, 12:10-18.
131. Hurtubise A., Bernstein M.L., Momparler R.L. Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int 2008, 8:16.
132. Okada T., Tanaka K., Nakatani F., et al. Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int J Cancer 2006, 118:90-97.
133. Folkman J. Angiogenesis. Ann Rev Med 2006, 57:1-18.
134. Balasubramanian L., Evens A.M. Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol 2006, 18:354-359.
135. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795-803.
136. Guan H., Zhou Z., Wang H., Jia S.F., Liu W., Kleinerman E.S. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 2005, 11:2662-2669.
137. Dalal S., Berry A.M., Cullinane C.J., et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005, 11:2364-2378.
138. Kaya M., Wada T., Akatsuka T., et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000, 6:572-577.
139. Kaya M., Wada T., Kawaguchi S., et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 2002, 86:864-869.
140. Maris J.M., Courtright J., Houghton P.J., et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:581-587.
141. Zhang L., Hannay J.A., Liu J., et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res 2006, 66:8770-8778.
142. Yin D., Jia T., Gong W., et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol 2008, 33:253-259.
143. Park H.R., Min K., Kim H.S., Jung W.W., Park Y.K. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas. Pathol Res Pract 2008, 204:575-582.
144. Gee M.F., Tsuchida R., Eichler-Jonsson C., Das B., Baruchel S., Malkin D. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005, 24:8025-8037.
145. Onisto M., Slongo M.L., Gregnanin L., Gastaldi T., Carli M., Rosolen A. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 2005, 27:791-798.
146. Bellamy W.T., Richter L., Frutiger Y., Grogan T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999, 59:728-733.
147. Masood R., Cai J., Zheng T., Smith D.L., Hinton D.R., Gill P.S. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001, 98:1904-1913.
148. Wu Y., Zhong Z., Huber J., et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006, 12:6573-6584.
149. Glade Bender J.L., Adamson P.C., Reid J.M., et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008, 26:399-405.
150. Benesch M., Windelberg M., Sauseng W., et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 2008, 19:807-813.
151. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract 2006, 3:24-40.
152. Bennicelli J.L., Barr F.G. Chromosomal translocations and sarcomas. Curr Opin Oncol 2002, 14:412-419.
153. Smith R., Owen L.A., Trem D.J., et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006, 9:405-416.
154. Bernasconi M., Remppis A., Fredericks W.J., Rauscher F.J., Schafer B.W. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci USA 1996, 93:13164-13169.
155. Jacobs JF, Coulie PG, Figdor CG, Adema GJ, de Vries IJ, Hoogerbrugge PM. Targets for active immunotherapy against pediatric solid tumors. Cancer Immunol Immunother 2008.
156. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (New York, NY) 2002, 298:850-854.
157. Dazzi F., Szydlo R.M., Goldman J.M. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol 1999, 27:1477-1486.
158. Mu L.J., Kyte J.A., Kvalheim G., et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005, 93:749-756.
159. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
160. Dagher R., Long L.M., Read E.J., et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002, 38:158-164.
161. Mackall C.L., Rhee E.H., Read E.J., et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008, 14:4850-4858.
162. van den Broeke L.T., Pendleton C.D., Mackall C., Helman L.J., Berzofsky J.A. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res 2006, 66:1818-1823.
163. Amstutz R., Wachtel M., Troxler H., et al. Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. Cancer Res 2008, 68:3767-3776.
164. Gardner KH, Montminy M. Can you hear me now? Regulating transcriptional activators by phosphorylation. Sci STKE 2005;pe44.
165. Houghton P.J., Morton C.L., Tucker C., et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007, 49:928-940.
166. Johnson J.I., Decker S., Zaharevitz D., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001, 84:1424-1431.
167. Voskoglou-Nomikos T., Pater J.L., Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003, 9:4227-4239.
168. Nardone R.M. Eradication of cross-contaminated cell lines: a call for action. Cell Biol Toxicol 2007, 23:367-372.
169. Neale G., Su X., Morton C.L., et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008, 14:4572-4583.
170. Sarfaraz S., Adhami V.M., Syed D.N., Afaq F., Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008, 68:339-342.
171. Wachtel M., Dettling M., Koscielniak E., et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004, 64:5539-5545.
172. Davicioni E., Finckenstein F.G., Shahbazian V., Buckley J.D., Triche T.J., Anderson M.J. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006, 66:6936-6946.
173. Croci S., Landuzzi L., Astolfi A., et al. Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res 2004, 64:1730-1736.
174. Jin Z., Lahat G., Korchin B., et al. Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target. Clin Cancer Res 2008, 14:5033-5042.
175. Cen L., Hsieh F.C., Lin H.J., Chen C.S., Qualman S.J., Lin J. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer 2007, 97:785-791.
176. Shor A.C., Keschman E.A., Lee F.Y., et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007, 67:2800-2808.
177. Marampon F., Ciccarelli C., Zani B.M. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer 2006, 5:31.
178. Ciccarelli C., Marampon F., Scoglio A., et al. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation, onco-phenotype reversal in rhabdomyosarcoma cells. Mol Cancer 2005, 4:41.
179. Greenberg J.A., Somme S., Russnes H.E., Durbin A.D., Malkin D. The estrogen receptor pathway in rhabdomyosarcoma: a role for estrogen receptor-beta in proliferation and response to the antiestrogen 4'OH-tamoxifen. Cancer Res 2008, 68:3476-3485.
180. Mercer S.E., Ewton D.Z., Shah S., Naqvi A., Friedman E. Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas. Cancer Res 2006, 66:5143-5150.
181. Ye L., Zhang H., Zhang L., et al. Effects of RNAi-mediated Smad4 silencing on growth and apoptosis of human rhabdomyosarcoma cells. Int J Oncol 2006, 29:1149-1157.
182. Barlow J.W., Wiley J.C., Mous M., et al. Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatr Blood Cancer 2006, 47:773-784.
183. Caldas H., Holloway M.P., Hall B.M., Qualman S.J., Altura R.A. Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo. J Med Genet 2006, 43:119-128.
184. Scotlandi K., Perdichizzi S., Bernard G., et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. Eur J Cancer 2006, 42:91-96.
185. Sanceau J., Poupon M.F., Delattre O., Sastre-Garau X., Wietzerbin J. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene 2002, 21:7700-7709.
186. Guan H., Zhou Z., Gallick G.E., et al. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther 2008, 7:1807-1816.
187. Maehara H., Kaname T., Yanagi K., et al. Midkine as a novel target for antibody therapy in osteosarcoma. Biochem Biophys Res Commun 2007, 358:757-762.
188. Zhang P., Yang Y., Zweidler-McKay P.A., Hughes D.P. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008, 14:2962-2969.
189. McGary E.C., Heimberger A., Mills L., et al. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res 2003, 9:6560-6566.
190. Contardi E., Palmisano G.L., Tazzari P.L., et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 2005, 117:538-550.
191. Warzecha J., Gottig S., Chow K.U., et al. Inhibition of osteosarcoma cell proliferation by the Hedgehog-inhibitor cyclopamine. J Chemother (Florence, Italy) 2007, 19:554-561.
192. Dass C.R., Friedhuber A.M., Khachigian L.M., Dunstan D.E., Choong P.F. Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer Biol Ther 2008, 7:1033-1036.
193. Dass C.R., Khachigian L.M., Choong P.F. C-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol Cancer Ther 2008, 7:1909-1912.
194. Wang R., Dong K., Lin F., et al. Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. Mol Med 2007, 13:567-575.
195. Zhang H.Z., Wang Y., Gao P., et al. Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells. Cancer Biol Ther 2006, 5:1457-1461.
196. Yuan K., Chung L.W., Siegal G.P., Zayzafoon M. Alpha-CaMKII controls the growth of human osteosarcoma by regulating cell cycle progression. Lab Invest 2007, 87:938-950.
197. Sato N., Mizumoto K., Maehara N., et al. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1. Anticancer Res 2000, 20:837-842.
198. Spreafico A., Schenone S., Serchi T., et al. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB J 2008, 22:1560-1571.